fianlimab: Clinical Trials

4 active not recruiting, 1 recruiting. 5 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	5	Active not recruiting 4, Recruiting 1
Phase 2	2	Active not recruiting 2

Follow fianlimab: new trials by email Literature Review of fianlimab trials Research Report on fianlimab

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) fianlimab, cemiplimab, relatlimab+nivolumab - Melanoma	Phase 3	Recruiting	Regeneron Pharmaceuticals	560	2024-09-09	2026-10-26
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer fianlimab, cemiplimab, Pemetrexed - Non-small Cell Lung Cancer	Phase 2 / Phase 3	Active not recruiting	Regeneron Pharmaceuticals	160	2023-08-08	2026-07-15
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) fianlimab, cemiplimab, Placebo - Advanced Non-Small Cell Lung Cancer	Phase 2 / Phase 3	Active not recruiting	Regeneron Pharmaceuticals	149	2023-06-30	2026-07-02
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery Fianlimab, Cemiplimab, Pembrolizumab - Melanoma	Phase 3	Active not recruiting	Regeneron Pharmaceuticals	1564	2023-01-16	2026-07-06
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Fianlimab, Cemiplimab, Pembrolizumab - Melanoma	Phase 3	Active not recruiting	Regeneron Pharmaceuticals	1546	2022-07-14	2026-04-22

Conditions studied

Melanoma (3)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Lung Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Skin Neoplasms (1)

Sponsors

Regeneron Pharmaceuticals (5)

Countries

Canada (5)  ·  United States (5)  ·  Australia (4)  ·  Georgia (4)  ·  Turkey (Türkiye) (4)  ·  Israel (3)  ·  Spain (3)  ·  Argentina (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Chile (2)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  Ireland (2)

Results publications

PMID 41811823

NIH funding

2023 (1)